Clinical Trial Update: Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating dose-dense ABVD as first-line therapy for early-stage unfavorable Hodgkin lymphoma, sponsored by Fondazione Italiana Li…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• ABVD

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Hodgkin Lymphoma | Phase 2 | Status: COMPLETED